21 May 2001 Transurethral holmium laser enucleation of prostates (HoLEP) larger than 80 g
Author Affiliations +
Proceedings Volume 4244, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XI; (2001) https://doi.org/10.1117/12.427809
Event: BiOS 2001 The International Symposium on Biomedical Optics, 2001, San Jose, CA, United States
Abstract
In this prospective study, the efficiency of HoLEP inpatients with prostates larger than 80 grams was to be evaluated. 64 urodynamically obstructed patients with prostate glands of 103 (80-230) grams of weight underwent HoLEP (80 W, 2.0 J, 40 Hz, 550 nm bare laser fibers). The resected weight was 70 (50-200) grams, the resection time was 120.5 (83-170) min., the average resection weight was 0.7 gm/min. The postoperative catheter time was 1.3 (1-3) days. The postoperative hospital stay was 2.5 (1-7) days. HoLEP induced a significant, pronounced and immediate improvement of lower urinary tract symptoms and micturition. The symptom score decreased from 22.3 preoperatively to 5.7 one week and 2.8 one year postoperatively. The peak urinary flow rate of 4.3 ml/sec preoperatively increased to 22 ml/sec one week and 32 ml/sec one year postoperatively. The residual urine dropped from 267 ml preoperatively to 11.5 ml one week and 5.0 ml one year postoperatively. There was one incident of postoperative arterial bleeding, one patient developed urethral stricture and two patients needed a second HoLEP. HoLEP appeared to be a highly effective treatment for prostates larger than 80 grams, with excellent functional results, minor blood loss, low complication rate and very short catheter time and hospital stay.
© (2001) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Rainer M. Kuntz, Rainer M. Kuntz, Karin Lehrich, Karin Lehrich, Amr Fayad, Amr Fayad, } "Transurethral holmium laser enucleation of prostates (HoLEP) larger than 80 g", Proc. SPIE 4244, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XI, (21 May 2001); doi: 10.1117/12.427809; https://doi.org/10.1117/12.427809
PROCEEDINGS
4 PAGES


SHARE
Back to Top